-
1
-
-
84861553275
-
A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: Analysis from the EVEREST trial
-
Gheorghiade M, Pang PS, Ambrosy AP, Lan G, Schmidt P, Filippatos G, Konstam M, Swedberg K, Cook T, Traver B, Maggioni A, Burnett J, Grinfeld L, Udelson J, Zannad F. A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial. Heart Fail Rev 2012;17:485-509.
-
(2012)
Heart Fail Rev
, vol.17
, pp. 485-509
-
-
Gheorghiade, M.1
Pang, P.S.2
Ambrosy, A.P.3
Lan, G.4
Schmidt, P.5
Filippatos, G.6
Konstam, M.7
Swedberg, K.8
Cook, T.9
Traver, B.10
Maggioni, A.11
Burnett, J.12
Grinfeld, L.13
Udelson, J.14
Zannad, F.15
-
2
-
-
80051990993
-
CONSENSUS to EMPHASIS: The overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure
-
McMurray JJ. CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure. Eur J Heart Fail 2011;13:929-936.
-
(2011)
Eur J Heart Fail
, vol.13
, pp. 929-936
-
-
McMurray, J.J.1
-
3
-
-
0037417252
-
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction
-
Pitt B, RemmeW, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348: 1309-1321.
-
(2003)
N Engl J Med
, vol.348
, pp. 1309-1321
-
-
Pitt, B.1
Remmew Zannad, F.2
Neaton, J.3
Martinez, F.4
Roniker, B.5
Bittman, R.6
Hurley, S.7
Kleiman, J.8
Gatlin, M.9
-
4
-
-
0033517302
-
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators
-
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717.
-
(1999)
N Engl J Med
, vol.341
, pp. 709-717
-
-
Pitt, B.1
Zannad, F.2
Remme, W.J.3
Cody, R.4
Castaigne, A.5
Perez, A.6
Palensky, J.7
Wittes, J.8
-
5
-
-
78650399880
-
Eplerenone in patients with systolic heart failure and mild symptoms
-
Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21.
-
(2011)
N Engl J Med
, vol.364
, pp. 11-21
-
-
Zannad, F.1
McMurray, J.J.2
Krum, H.3
Van Veldhuisen, D.J.4
Swedberg, K.5
Shi, H.6
Vincent, J.7
Pocock, S.J.8
Pitt, B.9
-
6
-
-
51749083776
-
Case detection, diagnosis, and treatment of patients with primary aldosteronism: An endocrine society clinical practice guideline
-
Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF Jr, Montori VM. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008;93:3266-3281.
-
(2008)
J Clin Endocrinol Metab
, vol.93
, pp. 3266-3281
-
-
Funder, J.W.1
Carey, R.M.2
Fardella, C.3
Gomez-Sanchez, C.E.4
Mantero, F.5
Stowasser, M.6
Young Jr., W.F.7
Montori, V.M.8
-
7
-
-
80052529403
-
Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics
-
Epstein M, Calhoun DA. Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics. J Clin Hypertens (Greenwich) 2011;13: 644-648.
-
(2011)
J Clin Hypertens (Greenwich)
, vol.13
, pp. 644-648
-
-
Epstein, M.1
Calhoun, D.A.2
-
8
-
-
33845302661
-
Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease
-
Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006;70:2116-2123.
-
(2006)
Kidney Int
, vol.70
, pp. 2116-2123
-
-
Bianchi, S.1
Bigazzi, R.2
Campese, V.M.3
-
9
-
-
38149030811
-
Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: A systematic review
-
Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 2008;51:199-211.
-
(2008)
Am J Kidney Dis
, vol.51
, pp. 199-211
-
-
Bomback, A.S.1
Kshirsagar, A.V.2
Amamoo, M.A.3
Klemmer, P.J.4
-
10
-
-
73349142401
-
Mineralocorticoid receptor blockers and chronic kidney disease
-
Jain G, Campbell RC, Warnock DG. Mineralocorticoid receptor blockers and chronic kidney disease. Clin J Am Soc Nephrol 2009;4:1685-1691.
-
(2009)
Clin J Am Soc Nephrol
, vol.4
, pp. 1685-1691
-
-
Jain, G.1
Campbell, R.C.2
Warnock, D.G.3
-
12
-
-
83455172574
-
A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome
-
Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, Mysiak A, O'Moore-Sullivan T, Marwick TH. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome. JACC Cardiovasc Imaging 2011;4:1239-1249.
-
(2011)
JACC Cardiovasc Imaging
, vol.4
, pp. 1239-1249
-
-
Kosmala, W.1
Przewlocka-Kosmala, M.2
Szczepanik-Osadnik, H.3
Mysiak, A.4
O'Moore-Sullivan, T.5
Marwick, T.H.6
-
13
-
-
70350733579
-
Use of aldosterone antagonists in heart failure
-
Albert NM, Yancy CW, Liang L, Zhao X, Hernandez AF, Peterson ED, Cannon CP, Fonarow GC. Use of aldosterone antagonists in heart failure. JAMA 2009;302:1658-1665.
-
(2009)
JAMA
, vol.302
, pp. 1658-1665
-
-
Albert, N.M.1
Yancy, C.W.2
Liang, L.3
Zhao, X.4
Hernandez, A.F.5
Peterson, E.D.6
Cannon, C.P.7
Fonarow, G.C.8
-
14
-
-
55149110356
-
Heart failure care in the outpatient cardiology practice setting: Findings from IMPROVE HF
-
Fonarow GC, Yancy CW, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, McBride ML, Mehra MR, O'Connor CM, Reynolds D, Walsh MN. Heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF. Circ Heart Fail 2008;1:98-106.
-
(2008)
Circ Heart Fail
, vol.1
, pp. 98-106
-
-
Fonarow, G.C.1
Yancy, C.W.2
Albert, N.M.3
Curtis, A.B.4
Stough, W.G.5
Gheorghiade, M.6
Heywood, J.T.7
McBride, M.L.8
Mehra, M.R.9
O'Connor, C.M.10
Reynolds, D.11
Walsh, M.N.12
-
15
-
-
77957244692
-
EURObservational Research Programme: The Heart Failure Pilot Survey (ESC-HF Pilot)
-
Maggioni AP, Dahlstrom U, Filippatos G, Chioncel O, Leiro MC, Drozdz J, Fruhwald F, Gullestad L, Logeart D, Metra M, Parissis J, Persson H, Ponikowski P, Rauchhaus M, Voors A, Nielsen OW, Zannad F, Tavazzi L. EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 2010;12:1076-1084.
-
(2010)
Eur J Heart Fail
, vol.12
, pp. 1076-1084
-
-
Maggioni, A.P.1
Dahlstrom, U.2
Filippatos, G.3
Chioncel, O.4
Leiro, M.C.5
Drozdz, J.6
Fruhwald, F.7
Gullestad, L.8
Logeart, D.9
Metra, M.10
Parissis, J.11
Persson, H.12
Ponikowski, P.13
Rauchhaus, M.14
Voors, A.15
Nielsen, O.W.16
Zannad, F.17
Tavazzi, L.18
-
16
-
-
0016687047
-
Antiandrogenic effect of spirolactones: Mechanism of action
-
Corvol P, Michaud A, Menard J, Freifeld M, Mahoudeau J. Antiandrogenic effect of spirolactones: mechanism of action. Endocrinology 1975;97:52-58.
-
(1975)
Endocrinology
, vol.97
, pp. 52-58
-
-
Corvol, P.1
Michaud, A.2
Menard, J.3
Freifeld, M.4
Mahoudeau, J.5
-
17
-
-
0035818917
-
Aldosterone in congestive heart failure
-
Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001;345: 1689-1697.
-
(2001)
N Engl J Med
, vol.345
, pp. 1689-1697
-
-
Weber, K.T.1
-
19
-
-
0035997359
-
Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension
-
Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002;15: 709-716.
-
(2002)
Am J Hypertens
, vol.15
, pp. 709-716
-
-
Weinberger, M.H.1
Roniker, B.2
Krause, S.L.3
Weiss, R.J.4
-
20
-
-
79954692757
-
A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism
-
Parthasarathy HK, Menard J, White WB, Young WF Jr, Williams GH, Williams B, Ruilope LM, McInnes GT, Connell JM, MacDonald TM. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens 2011;29:980-990.
-
(2011)
J Hypertens
, vol.29
, pp. 980-990
-
-
Parthasarathy, H.K.1
Menard, J.2
White, W.B.3
Young Jr., W.F.4
Williams, G.H.5
Williams, B.6
Ruilope, L.M.7
McInnes, G.T.8
Connell, J.M.9
MacDonald, T.M.10
-
21
-
-
33748637106
-
Mineralocorticoid-receptor blockade, hypertension and heart failure
-
Funder JW. Mineralocorticoid-receptor blockade, hypertension and heart failure. Nat Clin Pract Endocrinol Metab 2005;1:4-5.
-
(2005)
Nat Clin Pract Endocrinol Metab
, vol.1
, pp. 4-5
-
-
Funder, J.W.1
-
22
-
-
84856337738
-
Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics
-
Kolkhof P, Borden SA. Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics. Mol Cell Endocrinol 2012;350:310-317.
-
(2012)
Mol Cell Endocrinol
, vol.350
, pp. 310-317
-
-
Kolkhof, P.1
Borden, S.A.2
-
23
-
-
80755126650
-
Mineralocorticoid receptor antagonism: Therapeutic potential in acute heart failure syndromes
-
Albaghdadi M, Gheorghiade M, Pitt B. Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes. Eur Heart J 2011;32: 2626-2633.
-
(2011)
Eur Heart J
, vol.32
, pp. 2626-2633
-
-
Albaghdadi, M.1
Gheorghiade, M.2
Pitt, B.3
-
24
-
-
0033574249
-
A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group
-
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-170.
-
(1999)
Ann Intern Med
, vol.130
, pp. 461-170
-
-
Levey, A.S.1
Bosch, J.P.2
Lewis, J.B.3
Greene, T.4
Rogers, N.5
Roth, D.6
-
25
-
-
77956909015
-
A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule
-
Fagart J, Hillisch A, Huyet J, Barfacker L, Fay M, Pleiss U, Pook E, Schafer S, Rafestin-Oblin ME, Kolkhof P. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem 2010;285: 29932-29940.
-
(2010)
J Biol Chem
, vol.285
, pp. 29932-29940
-
-
Fagart, J.1
Hillisch, A.2
Huyet, J.3
Barfacker, L.4
Fay, M.5
Pleiss, U.6
Pook, E.7
Schafer, S.8
Rafestin-Oblin, M.E.9
Kolkhof, P.10
-
26
-
-
84861554853
-
Discovery of BAY 94-8862: A non-steroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases
-
in press
-
Bärfacker L, Kuhl A, Hillisch A, Grosser R, Figueroa-Pérez S, Heckroth H, Nitsche A, Ergüden JK, Gielen-Haertwig H, Schlemmer KH, Mittendorf J, Paulsen H, Platzek J, Kolkhof P. Discovery of BAY 94-8862: a non-steroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem 2012; in press.
-
(2012)
ChemMedChem
-
-
Bärfacker, L.1
Kuhl, A.2
Hillisch, A.3
Grosser, R.4
Figueroa-Pérez, S.5
Heckroth, H.6
Nitsche, A.7
Ergüden, J.K.8
Gielen-Haertwig, H.9
Schlemmer, K.H.10
Mittendorf, J.11
Paulsen, H.12
Platzek, J.13
Kolkhof, P.14
-
27
-
-
77952727090
-
Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines
-
Arhancet GB, Woodard SS, Dietz JD, Garland DJ, Wagner GM, Iyanar K, Collins JT, Blinn JR, Numann RE, Hu X, Huang HC. Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines. J Med Chem 2010;53:4300-4304.
-
(2010)
J Med Chem
, vol.53
, pp. 4300-4304
-
-
Arhancet, G.B.1
Woodard, S.S.2
Dietz, J.D.3
Garland, D.J.4
Wagner, G.M.5
Iyanar, K.6
Collins, J.T.7
Blinn, J.R.8
Numann, R.E.9
Hu, X.10
Huang, H.C.11
-
28
-
-
39749199510
-
A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity
-
Dietz JD, Du S, Bolten CW, Payne MA, Xia C, Blinn JR, Funder JW, Hu X. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension 2008;51:742-748.
-
(2008)
Hypertension
, vol.51
, pp. 742-748
-
-
Dietz, J.D.1
Du, S.2
Bolten, C.W.3
Payne, M.A.4
Xia, C.5
Blinn, J.R.6
Funder, J.W.7
Hu, X.8
-
29
-
-
67649470527
-
The frequency of hyperkalemia and its significance in chronic kidney disease
-
Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, Weir MR, Fink JC. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 2009;169:1156-1162.
-
(2009)
Arch Intern Med
, vol.169
, pp. 1156-1162
-
-
Einhorn, L.M.1
Zhan, M.2
Hsu, V.D.3
Walker, L.D.4
Moen, M.F.5
Seliger, S.L.6
Weir, M.R.7
Fink, J.C.8
|